The risk of women developing multiple sclerosis (MS) is higher than that for men. In the last decades of the 20th century, the incidence of MS in females nearly doubled in many countries, while it has remained virtually unchanged for men. Studies designed to investigate change in MS sex ratio over time in different countries showed that this increase is more pronounced in areas located in the most northern latitudes 1-3 than in those in southern latitudes where a high sex ratio disequilibrium appears to be stable over time. 4 Inaccuracy of diagnosis and differences in ascertainment and study design might play a role in the geographical and temporal variations. However, a direct comparison of uniformly collected data in an international database demonstrated an uneven distribution of sex ratio time-trends among populations from different geographical areas, confirming a latitudinal gradient of this increase. 5 A recent study, based on several thousand MS patients, identified through the Swedish MS registry (SMSreg), contradicted this notion. 6 In this study there was no evidence for an increasing F/M ratio either in the prevalence proportion by year of birth (performed between 1931 and 1985) or in the incidence rates by year of onset (performed between 1946 and 2005).
Interestingly, in this issue of Multiple Sclerosis Journal, Westerlind and collaborators 7 reinvestigate the sex ratio trends of MS in Sweden on a larger dataset derived from the combination of data collected in the SMSreg with those in the Swedish National Patient Register (PAR). The new analysis, performed on 19,510 patients born in Sweden between 1931 and 1985, shows, unlike the previous analysis, an increase in sex ratio from 1.70 for patients born in the 1930s to 2.67 for patients born in the 1980s.
What are the reasons underlying the different results obtained in the first and second analysis? Thanks to the availability of a unique personal identifying number (PIN) which is assigned to everyone at birth or at immigration since 1961 in Sweden, the authors were able to gather information on the same person in several nationwide registries (SMSreg, PAR, Swedish National Population Registry and Cause of Death Registry). Through cross-linking of data derived from these different sources, the authors demonstrate that MS population coverage in the SMSreg changed over time and differed between sexes, and that the difference was due to a higher mortality rate in men born in the 1930s when compared with women. This resulted in a bias toward a higher participation of women among older patients in SMSreg and a consequent Type II error in the previous report.
This study is relevant because it highlights important issues relative to ascertainment methods in epidemiological studies. It carefully demonstrates that the use of long-lasting population-based registries and multiple linkages to several independent and complete national sources of notification is critical for minimizing a patient participation bias that may be present in clinically based studies. Moreover, the study outlines that a change in the survival rate in women compared with men may represent a serious confounder in epidemiological studies such as those designed to investigate F/M sex ratio trends over time.
Some weaknesses of this study also warrant discussion. The final study dataset is reported to be half derived from the SMSreg (introduced in 1997) and half from the PAR (introduced in 1968) which may imply different levels of ascertainments of data collection. Although a validation of the data derived from the PAR is reported in a previous paper, 8 underpinning the use of linked health data sources is the need for a continuous control of the quality of data within a single source as well as between multiple sources. A further consideration in the present study (12) is that information on age at onset of the MS study population was not available in the PAR so the analyses of sex ratio trends over time did not adjust for age at onset (but for the age at first occurrence in the PAR) within each birth-year subgroup. This is an important point because some of the recent cohorts, included in the analysis, are still young (e.g. those born between 1981 and 1985) and, since the age at MS onset in women tends to be younger than in men, the F/M ratio in the younger groups may be biased upward.
Despite these limitations inherent to the methodology, the results of this study, on a large sample size covering the whole country, carry solid confirmation of a F/M increase in Sweden, similar to that found in other western countries at northern latitudes. The lack of information, in the PAR, on patients' clinical course, unfortunately, prevents the issue of sex ratios for the different disease courses being addressed. However most of the previous studies consistently showed that the F/M ratio increase mainly affects patients with relapsing onset MS, and is not seen in primary progressive MS.
The reasons for the growing female preponderance in MS patients remains speculative. Underlying gender-related factors might be hormonal or environmental or due to gene-environment interactions. 9 Changes in women's lifestyle (i.e. use of contraceptives, dietary changes, obesity, smoking behaviour, roles in the workforce, sunlight exposure, vitamin D deficiency) and in particular higher age at first childbirth or fewer pregnancies could contribute to the increasing incidence of MS in women. 10 To date, however, little direct evidence has been found for any of these factors. In this respect the use of high quality and long-lasting population-based registries may be useful for casecontrol studies, since they may enable the selection of a matched non-exposed group and provide accurate estimates of exposure time and relative risk.
All these considerations underscore the importance of international initiatives to accelerate availability of linked electronic health records (from disease registry, primary care, hospital care and death certificates) at a national level, and to create a big international MS data pool by merging national registers, for future more reliable epidemiological and clinical studies in MS.
